세계 수술 부위 감염 관리 시장 규모는 2024년 48억 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2033년까지 67억 달러에 달하고, 2025-2033년 3.59%의 연평균 성장률(CAGR)을 보일 것으로 전망하고 있습니다. 외과 수술 증가, 의료 관련 감염에 대한 인식 증가, 환자 안전에 대한 관심 증가, 의료비 급증 등이 시장 성장을 가속하는 주요 요인으로 꼽힙니다.
주요 시장 성장 촉진요인 : 고령화, 좌식 생활습관, 건강에 해로운 식습관 등으로 인해 병원 내 감염이 증가하고 암, 소화기 질환, 심혈관 질환(CVDs)과 같은 만성 질환의 유병률이 증가함에 따라 수술 부위 감염 관리의 채택을 촉진하고 있습니다. 또한, 각국의 정부 및 비정부 기관에서 엄격한 지침 도입, 감염 관리 실천에 초점을 맞춘 교육 프로그램 등 여러 가지 유리한 이니셔티브를 시행하고 있는 것도 수술 부위 감염 관리 시장을 촉진하고 있습니다.
주요 시장 동향 : 수술 부위 감염 증가, 감염 제어 제품의 지속적인 기술 발전, 최소 침습 수술의 채택 증가, 엄격한 규제 기준의 도입 등이 수술 부위 감염 관리 시장 수요를 촉진할 것으로 예측됩니다. 또한, 전 세계 의료비 지출이 증가함에 따라 환자 예후를 개선하고 SSI를 포함한 의료 관련 감염을 줄이는 데 관심이 집중되고 있습니다. 이러한 추세는 수술 환경에서 고급 감염 관리 솔루션에 대한 수요를 촉진할 것으로 예측됩니다.
경쟁 구도: 수술 부위 감염 관리 시장의 주요 기업으로는 3M Company, Ansell Limited, Becton Dickinson and Company, bioMerieux SA(Institut Merieux), Covalon Technologies Ltd. GAMA Healthcare Ltd., Getinge AB(Carl Bennet AB), Johnson &Johnson, Kimberly-Clark Corporation, Molnlycke Health Care AB, Prescient Surgical, Steris Corporation 등이 있습니다.
지리적 동향 : 보고서에 따르면, 북미는 현재 전체 시장을 지배하고 있습니다. 이 지역은 수술 부위 감염 관리 제품 및 서비스 분야에서 세계 최대 시장입니다. 시장 규모는 수술 건수 증가, 높은 수준의 의료 인프라, 광범위한 규제, 지속적인 기술 혁신 등의 요인에 영향을 받고 있습니다. 의료 관련 감염에 대한 인식이 높아지고 감염 예방 조치의 중요성이 부각되면서 시장은 꾸준히 성장하고 있습니다.
과제와 기회: 항생제 내성, 컴플라이언스 문제, 비용 고려, 의료 시설에 따른 수술 방법 및 프로토콜의 차이 등은 시장이 직면하고 있는 과제 중 일부입니다. 그러나 항균성 코팅, 새로운 수술 재료, 로봇 보조 수술의 개발과 같은 의료 기술 동향은 수술 부위 감염 관리 시장에 수술 환경에서의 감염 관리를 강화할 수 있는 최근 기회를 제공합니다.
노령인구 증가
세계 많은 지역에서 65세 이상 노인의 비율이 증가하는 인구 통계학적 변화가 일어나고 있습니다. 예를 들어, 세계보건기구(WHO)에 따르면 2030년까지 전 세계 인구 6명 중 1명이 60세 이상이 될 것이라고 합니다. 이때 60세 이상 인구 비율은 2020년 10억 명에서 14억 명으로 증가하고, 2050년에는 세계 60세 이상 인구가 2배(21억 명)로 증가하며, 80세 이상 인구는 2020년에서 2050년 사이에 3배 증가하여 4억 2,600만 명에 달할 것으로 예측됩니다. 노인은 노화에 따른 면역체계의 변화, 조직 치유 능력의 저하, 당뇨병, 고혈압, 심혈관 질환 등의 동반 질환의 존재로 인해 SSI에 더 취약합니다. 노령인구가 증가함에 따라 노인의 수술 건수도 증가하여 SSI의 위험을 줄이기 위한 감염 관리 대책에 대한 요구가 증가하고 있습니다. 예를 들어, 2021년 3월 국립의학도서관이 발표한 논문에 따르면, 65세 이상 노인을 대상으로 매년 400만 건에 가까운 수술이 시행되고 있습니다. 이와 유사하게, 2023년 3월 국립의학도서관이 발표한 또 다른 논문에 따르면, 인공 슬관절 전치환술의 경우 61-65세 연령층에 비해 76-80세 노년층에서 SSI 발생률이 높았습니다. 이러한 요인들은 수술 부위 감염 시장의 수익을 더욱 증가시키고 있습니다.
수술기법 증가와 의료 인프라 발전
세계적으로 외과 수술이 크게 증가하고 있습니다. 예를 들어, 미국 국립의학도서관이 발표한 논문에 따르면 2020년 9월, 전 세계 질병 부담의 11%가 외과적 개입, 마취 관리 또는 두 가지 모두를 필요로 한다고 합니다. 가장 많은 수술은 백내장(22.8%), 제왕절개(3.8%), 골절 수술(3.27%), 탈장(2.86%) 순으로 나타났습니다. 필요한 수술은 전체 수술의 44.2%를 차지했습니다. 또한, 특히 신흥국 시장의 의료 인프라 개발 노력은 수술 부위 감염 관리 시장의 성장에 기여하고 있으며, India Investment Grid가 발표한 기사에 따르면 공공 의료 지출은 2025년까지 GDP의 2.5%로 증가할 것으로 예측됩니다. 이와는 별도로, 의료 시설과 의료 서비스 제공업체는 SSI 발생을 최소화하기 위해 예방 전략과 기술에 대한 투자를 늘리고 있습니다. 여기에는 엄격한 프로토콜 채택, 첨단 멸균 기술, 수술 도구의 항균 코팅, 상처 드레싱 및 봉합사에 첨단 소재 사용 등이 포함됩니다. 예를 들어, 2023년 12월, 플린더스 대학과 중국 연구진은 공동으로 감염에 강한 새로운 Ag-Ga 정형외과용 임플란트 피복재를 개발했습니다. 이 신소재는 수많은 의료기기에 스프레이 캐스트하여 감염으로부터 보호하고 동시에 항염증 작용을 발휘하기 때문에 쉽고 제어할 수 있습니다. 또한, 2023년 10월, Sylke Inc.는 순수 저자극성 실크 섬유소로 제조된 드레싱 소재인 SYLKE를 출시하여 수술 상처의 치유를 촉진하고 흉터 형성 부전의 원인이 되는 합병증과 감염을 감소시키며, SYLKE는 감염과 열악한 흉터 형성을 유발하는 의료용 접착제와 관련된 의료용 접착제와 관련된 피부 손상을 제거함으로써 수술 상처 관리의 혁신을 목표로 합니다.
연구 및 임상시험의 발전
연구개발 및 임상시험의 발전은 혁신적인 제품 개발을 촉진하고, 치료 전략을 강화하며, 환자 결과를 개선함으로써 수술 부위 감염 관리 시장의 성장을 가속하는 데 중요한 역할을 하고 있습니다. 예를 들어, 2024년 2월, 수술 예후를 개선하는 바이오 제약 기업 폴리피드(Polypid)는 100번째 환자를 등록한 후 SHIELD II 3상 임상시험에서 큰 진전을 이루었습니다고 발표했습니다. 이 연구는 복부 대장 수술에서 수술 부위 감염(SSI)을 예방하기 위한 제품 후보인 D-PLEX100의 효능을 조사했으며, SHIELD II 임상의 최종 결과는 2024년 하반기에 발표될 것으로 예상되며, 약 40개 기관이 이 임상에 적극적으로 참여하고 있습니다. 또한, 연구 및 임상시험은 수술 환경에서 감염 예방 및 통제를 위한 모범 사례와 가이드라인을 확인하는 데 기여하고 있습니다. 수술 전 준비, 수술 절차, 항균제 예방, 수술 후 관리에 대한 근거에 기반한 권장사항은 프로토콜을 표준화하고 감염 관리 준수율을 향상시켜 궁극적으로 SSI 발생률을 낮추고 환자 예후를 개선하는 데 도움이 될 것입니다. 예를 들어, 2023년 8월 에모리 대학에서 2만 명 이상의 환자를 대상으로 자동화된 방식으로 피드백을 제공하고 성과를 평가한 결과, 항생제 예방 투약 준수율이 12% 증가했고, SSI 전체가 33% 감소했습니다. Society(외과감염학회) 2023 연례총회에서 발표된 데이터에 따르면, 독자적인 자동화된 항생제 예방투여 접근법이 수술 부위 감염을 크게 감소시키는 것으로 나타났습니다. 이러한 요인들은 수술 부위 감염 관리 시장 예측에 더욱 긍정적인 영향을 미치고 있습니다.
The global surgical site infection control market size reached USD 4.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.7 Billion by 2033, exhibiting a growth rate (CAGR) of 3.59% during 2025-2033. The increasing surgical procedures, growing awareness about healthcare-associated infections, enhanced focus on patient safety, and surging healthcare expenditure are some of the major factors propelling the market growth.
Major Market Drivers: The rising cases of hospital-acquired infections and the increasing prevalence of chronic conditions, such as cancer, gastrointestinal disorders, cardiovascular diseases (CVDs), etc., due to the aging population, sedentary lifestyles, and unhealthy eating habits are propelling the adoption of surgical site infection control. Moreover, several favorable initiatives undertaken by the governing and non-governing agencies of various countries, such as the introduction of stringent guidelines and training programs focused on infection control practices, are propelling the surgical site infection control market.
Key Market Trends: The increasing prevalence of surgical site infections, ongoing technological advancements in infection control products, rising adoption of minimally invasive surgeries, and introduction of stringent regulatory standards are expected to propel the surgical site infection control market demand. Moreover, with the rise in healthcare expenditure globally, there is a growing focus on improving patient outcomes and reducing healthcare-associated infections, including SSIs. This trend is expected to drive the demand for advanced infection control solutions in surgical settings.
Competitive Landscape: Some of the leading surgical site infection control market companies are 3M Company, Ansell Limited, Becton Dickinson and Company, bioMerieux SA. (Institut Merieux), Covalon Technologies Ltd., GAMA Healthcare Ltd., Getinge AB (Carl Bennet AB), Johnson & Johnson, Kimberly-Clark Corporation, Molnlycke Health Care AB, Prescient Surgical, and Steris Corporation, among many others.
Geographical Trends: According to the report, North America currently dominates the overall market. The region represents one of the largest markets for surgical site infection control products and services globally. The market size is influenced by factors such as the increase in the number of surgical procedures, advanced healthcare infrastructures, wide presence of regulatory landscape, ongoing technological innovations, etc. The market has been experiencing steady growth due to the increasing awareness about healthcare-associated infections and the importance of infection prevention measures.
Challenges and Opportunities: Antibiotic resistance, compliance issues, cost consideration, and variations in surgical practices and protocols across different healthcare facilities are some of the challenges that the market is facing. However, advances in medical technology, such as the development of antimicrobial coatings, novel surgical materials, and robotic-assisted surgery, offer the surgical site infection control market recent opportunities to enhance infection control in surgical settings.
Rising Geriatric Population
Many regions worldwide are experiencing a demographic shift characterized by a growing proportion of older adults aged 65 and above. For instance, according to the World Health Organization, by 2030, one in every six persons in the world will be 60 or older. At this time, the proportion of the population aged 60 and up will rise from 1 billion in 2020 to 1.4 billion. By 2050, the global population of persons aged 60 and up will double (2.1 billion). The number of people aged 80 and older is anticipated to treble between 2020 and 2050, reaching 426 million. Older adults are more vulnerable to SSIs due to age-related changes in the immune system, reduced tissue healing capacity, and the presence of comorbidities such as diabetes, hypertension, and cardiovascular disease. As the geriatric population grows, there is a corresponding increase in the number of surgical procedures performed on older adults, leading to a higher demand for infection control measures to mitigate the risk of SSIs. For instance, according to an article published by the National Library of Medicine in March 2021, nearly 4 million surgical procedures were performed each year in older adults aged 65 years and above. In line with this, according to another article published by the National Library of Medicine in March 2023, in total knee replacement surgery, the SSI rates were higher in older adults aged 76-80 years when compared with the age group of 61-65 years. These factors are further bolstering the surgical site infection market revenue.
Increasing Surgical Procedure and Healthcare Infrastructure Development
There has been a significant increase in surgical procedures across the world. For instance, according to an article published by the National Library of Medicine, in September 2020, 11% of the world's illness burden necessitates surgical intervention, anesthetic management, or both. The most common procedures were for cataracts (22.8%), Caesareans (3.8%), fracture surgeries (3.27%), and hernias (2.86%). The necessary operations made up 44.2% of all surgeries. Moreover, healthcare infrastructure development initiatives, particularly in emerging markets, contribute to the growth of the surgical site infection control market. According to an article published by the India Investment Grid, public health expenditure is expected to rise to 2.5% of GDP by 2025. Apart from this, healthcare facilities and providers are increasingly investing in preventive strategies and technologies to minimize the incidence of SSIs. This includes the adoption of stringent protocols, advanced sterilization techniques, antimicrobial coatings for surgical instruments, and the utilization of high-tech materials in wound dressings and sutures. For instance, in December 2023, Flinders University and Chinese researchers collaborated to develop a new Ag-Ga orthopedic implant covering that is highly resistant to infection. The novel material could be readily and controllably put by spray-casting on numerous medical devices to protect them from infection while simultaneously providing an anti-inflammatory impact. Moreover, in October 2023, Sylke Inc. introduced SYLKE, the dressing manufactured from pure hypoallergenic silk fibroin. SYLKE promotes healing in surgical wounds and reduces complications and infections that might cause poor scarring. SYLKE seeks to transform surgical wound care by removing medical adhesive-related skin damage that causes infections and poor scarring outcomes.
Advances in Research Studies and Clinical Trials
Advances in research studies and clinical trials play a crucial role in driving growth in the surgical site infection control market by facilitating the development of innovative products, enhancing treatment strategies, and improving patient outcomes. For instance, in February 2024, PolyPid Ltd., a biopharmaceutical company dedicated to improving surgical outcomes, announced considerable progress in its SHIELD II Phase 3 clinical study, after enrolling its 100th patient. This research looked at the efficacy of D-PLEX100, a product candidate intended to prevent surgical site infections (SSIs) in abdominal colorectal procedures. Top-line results from the SHIELD II trial were expected in the second half of 2024, with about 40 locations actively participating in the study. Moreover, research studies and clinical trials contribute to the identification of best practices and guidelines for infection prevention and control in surgical settings. Evidence-based recommendations regarding preoperative preparation, surgical techniques, antimicrobial prophylaxis, and postoperative care help standardize protocols and improve adherence to infection control measures, ultimately reducing the incidence of SSIs and improving patient outcomes. For instance, in August 2023, Emory University performed research which included over 20,000 patients and used automated methods to provide feedback and evaluate performance, found a 12% increase in antibiotic prophylactic compliance and a 33% decrease in overall SSIs. Data presented at the Surgical Infection Society's 2023 annual meeting showed that a unique automated antibiotic prophylaxis approach significantly reduces surgical site infections. These factors are further positively influencing the surgical site infection control market forecast.
Antibiotic prophylaxis products currently exhibit a clear dominance in the market
According to the surgical site infection control market outlook, antibiotic prophylaxis plays a crucial role in preventing surgical site infections (SSIs), which are a significant concern in healthcare settings. Antibiotics are usually administered shortly before surgical incision to achieve adequate tissue concentrations at the time of potential bacterial contamination. The timing of administration is critical and should ideally occur within 60 minutes before the surgical incision, although exceptions may exist for certain antibiotics and procedures. Moreover, prophylactic antibiotic regimens are often tailored to the specific requirements of different surgical procedures. For example, orthopedic surgeries may require coverage against Staphylococcus aureus and streptococci, while colorectal surgeries may necessitate additional coverage against gram-negative and anaerobic bacteria. For instance, in January 2024, the American Association for the Surgery of Trauma (AAST), the World Surgical Infection Society Europe (SIS-E), the Global Alliance for Infection in Surgery (GAIS), and the World Society of Emergency Surgery (WSES) collaborated to develop important guidelines for antibiotic prophylaxis (AP) in cases of traumatic lesions involving the head, brain, torso, maxillofacial region, extremities, skin, and soft tissues.
Currently, superficial incisional SSI accounts for the majority of the global market share
According to the surgical site infection market overview, superficial incisional surgical site infections (SSIs) represent a significant portion of all SSIs. These infections occur within 30 days after the operation and involve only the skin and subcutaneous tissue of the incision. They are often characterized by symptoms such as redness, warmth, swelling, and localized pain at the surgical site. They are among the most common types of SSIs encountered in surgical practice. Their relatively high incidence underscores their importance in infection control efforts. For instance, according to an article published by the National Library of Medicine in 2023, 59% of the total SSI patients had superficial SSI.
Cesarean section currently holds the largest market share
Cesarean sections are one of the most common surgical procedures globally. In many countries, the rates of C-section deliveries have been increasing steadily over the years. With such a high volume of procedures, the prevention of SSIs in C-sections becomes a significant focus of infection control efforts. Moreover, the surgical site in a Cesarean section is particularly vulnerable to infection due to its proximity to the genital and gastrointestinal tracts, which harbor numerous bacteria. Additionally, the procedure involves breaching the protective barriers of the skin and uterine wall, increasing the risk of contamination. Apart from this, SSIs following Cesarean sections can have serious consequences for both the mother and the newborn. In addition to causing discomfort and prolonging hospital stays for the mother, SSIs can lead to complications such as endometritis, wound dehiscence, sepsis, and increased healthcare costs. There's also a risk of vertical transmission of pathogens to the newborn, which can result in neonatal infections. For instance, according to World Health Organization (WHO) data, the use of cesarean sections is increasing, accounting for more than one in every five (21%) childbirths in 2021. This figure is expected to rise further over the next decade, with almost one-third (29%) of all births by cesarean section by 2030.
Currently, hospitals exhibit a clear dominance in the market
The demand for surgical site infection (SSI) control in hospitals arises from various factors related to patient safety, healthcare quality, regulatory requirements, and financial considerations. Preventing SSIs is essential for ensuring patient safety and minimizing the risk of postoperative complications. SSIs can lead to significant morbidity, prolonged hospital stays, increased healthcare costs, and in severe cases, mortality. Hospitals have a moral and ethical obligation to provide safe and high-quality care to their patients, which includes implementing measures to control SSIs. Moreover, hospitals are increasingly focused on delivering high-quality care and maintaining a positive reputation within their communities. Preventing SSIs is a fundamental aspect of healthcare quality improvement efforts. Hospitals that effectively control SSIs are perceived as safer and more reliable by patients, healthcare professionals, insurers, and regulatory agencies.
North America currently dominates the global market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America currently dominates the global market.
According to the surgical site infection control market statistics, North America represents one of the largest markets for healthcare products and services globally. Within this context, the SSI control market encompasses a wide range of products, including antimicrobial agents, surgical drapes, gloves, sterilization equipment, wound care products, and surveillance systems. Despite advances in surgical techniques and infection control practices, SSIs remain a significant concern in North American healthcare facilities. The prevalence of SSIs varies across different surgical specialties and settings but represents a substantial clinical and economic burden on healthcare systems. For instance, in February 2021, Penn Medicine opened its new Interventional Support Center (ISC), making it one of the most prominent instrument processing and surgical supply preparation facilities in Southwest Philadelphia, United States. The ISC is one of Pennsylvania's first facilities of its sort, with staff sterilizing and packaging thousands of instruments daily in preparation for surgeries and procedures, ranging from basic scissors and clamps to complex robotic instruments. For instance, according to an article published by the National Library of Medicine, in February 2024, surgical site infections accounted for approximately two million nosocomial infections in the U.S., which considerably raises postoperative morbidity and mortality rates. In line with this, according to the international trial co-led by McMaster University and the University of Maryland School of Medicine in February 2024, thousands of patients yearly undergoing surgery for a closed fracture may avoid surgical site infections by using iodine povacrylex in alcohol to disinfect their skin.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
May 2024: Nanordica Medical, an Estonian medical technology firm, received €1.75 million to enter the market with first-in-class wound care solutions that treat serious wounds.
April 2024: Vomaris launched PowerHeal, a bioelectric bandage approved by the FDA for over-the-counter (OTC) use in the management of wounds.
February 2024: PolyPid Ltd., a biopharmaceutical company dedicated to improving surgical outcomes, announced considerable progress in its SHIELD II Phase 3 clinical study, after enrolling its 100th patient. This research looked at the efficacy of D-PLEX100, a product candidate intended to prevent surgical site infections (SSIs) in abdominal colorectal procedures.